GSK 2981278

CAS No. 1474110-21-8

GSK 2981278( GSK2981278 | GSK-2981278 )

Catalog No. M12032 CAS No. 1474110-21-8

GSK 2981278 (GSK2981278) is a potent, highly selective RORγ/RORγt inhibitor that potently inhibits IL-17A and IL-22 protein secretion in human peripheral T cell with IC50 of 3.2 nM.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 70 In Stock
10MG 106 In Stock
50MG 302 In Stock
100MG 448 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    GSK 2981278
  • Note
    Research use only, not for human use.
  • Brief Description
    GSK 2981278 (GSK2981278) is a potent, highly selective RORγ/RORγt inhibitor that potently inhibits IL-17A and IL-22 protein secretion in human peripheral T cell with IC50 of 3.2 nM.
  • Description
    GSK 2981278 (GSK2981278) is a potent, highly selective RORγ/RORγt inhibitor that potently inhibits IL-17A and IL-22 protein secretion in human peripheral T cell with IC50 of 3.2 nM; shows no effects on RORα-dependent activation; robustly inhibits RORγ-mediated cytokine production at both the mRNA and protein level, inhibits RORγt-mediated transactivation; attenuates inflammation in mouse model of psoriasis.Psoriasis Phase 2 Clinical(In Vitro):GSK2981278 markedly and potently inhibits IL-17A and IL-22 protein secretion in a concentration dependent manner (IC50 = 3.2 nM) during 5 days of culture under Th17 skewing conditions.GSK2981278 (0.3, 1, 3, 10, 30, 100, 300, 1000 pM; 5 day) potently and selectively inhibits IL-17 and IL-22 levels. Culture in the presence of ≥3 nM GSK2981278 led to a near-complete inhibition of IL-17A protein secretion.(In Vivo):GSK2981278 (1% in ointment; topically; for three days) reduces skin redness and scaling, as well as decreased hyperplasia, as evidenced by a 23% reduction in epidermal thickness. GSK2981278 attenuates inflammation in a mouse model of psoriasis.
  • In Vitro
    ——
  • In Vivo
    Animal Model:BALB/c JByRj Female Mice (8 week-old at study initiation; imiquimod (IMQ) mouse model) Dosage:1% Administration:In ointment; topically; for three days Result:Reduced skin redness and scaling, as well as decreased hyperplasia, as evidenced by a 23% reduction in epidermal thickness.
  • Synonyms
    GSK2981278 | GSK-2981278
  • Pathway
    Nuclear Receptor/Transcription Factor
  • Target
    ROR
  • Recptor
    RORγ
  • Research Area
    Inflammation/Immunology
  • Indication
    Psoriasis

Chemical Information

  • CAS Number
    1474110-21-8
  • Formula Weight
    461.617
  • Molecular Formula
    C25H35NO5S
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: 10 mM ( < 1 mg/ml refers to the product slightly soluble or insoluble )
  • SMILES
    O=S(C1=CC=C(OCC2CCOCC2)C(CO)=C1)(N(C3=CC=C(CC)C=C3)CC(C)C)=O
  • Chemical Name
    N-(4-Ethylphenyl)-3-(hydroxymethyl)-N-(2-methylpropyl)-4-[(tetrahydro-2H-pyran-4-yl)methoxy]benzenesulfonamide

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Kang EG, et al. Br J Dermatol. 2017 Nov 18. doi: 10.1111/bjd.16131. 2. Smith SH, et al. PLoS One. 2016 Feb 12;11(2):e0147979.
molnova catalog
related products
  • SR2211

    SR2211 is a specific modulator and an inverse agonist of RORγ(IC50 = 320 nM, Ki = 105 nM).

  • Bevurogant

    Bevurogant is an antagonist of RORγt receptor and can be used in studies about the treatment of chronic inflammatory diseases.

  • RORγt inverse agonis...

    RORγt inverse agonist 13 (Compound 3i) is a potent, orally active and selective RORγt inverse agonist (IC50=63.8 nM), with improved drug-like properties.